Prof. Baudouin Standaert | Health Economics of Vaccines | Best Researcher Award
Prof. Baudouin Standaert, UHasselt, Belgium.
Dr. Baudouin “Bo” Standaert is a highly accomplished Belgian health economist, epidemiologist, and guest professor at the University of Hasselt. His extensive career spans health economics, epidemiology, and global health, with significant contributions to vaccine-related economic evaluations.
Profile
Strengths
Dr. Baudouin “Bo” Standaert has an impressive career in epidemiology and health economics, demonstrating deep expertise through a broad range of roles in both academia and industry. His extensive experience in public health, management, and epidemiology is highlighted by his role as Director of HEBO bv, where he leads projects in advanced data evaluation, cost-effectiveness, and health economics modeling. Dr. Standaert has made significant contributions to vaccine development and public health policy, having worked on the economic value of vaccines and built health economics programs at major pharmaceutical companies like GSK and AMGEN. His over 66 peer-reviewed publications and various awards, including recognitions from ISPOR, further underscore his research quality and impact in health economics. Dr. Standaert has also shown leadership and commitment to public health through his collaborations with international organizations like WHO and his contributions to health economic guidelines for vaccines.
Areas for Improvement
Despite his achievements, Dr. Standaert’s work could benefit from increased visibility in interdisciplinary public health forums to expand his influence beyond the health economics and vaccine research communities. Further exploration of preventive health economic models applicable to emerging infectious diseases and global health challenges could also diversify his contributions. Additionally, there could be more focused efforts on training young researchers to ensure knowledge transfer and continued progress in health economics.
Education ๐
Dr. Standaert holds an MD from the Catholic University of Leuven and multiple advanced degrees in Epidemiology (University of Massachusetts), Public Health, Health Economics (UIA Antwerp), and a PhD in Health Economics from the University of Groningen. His education is complemented by various specialized training, including in tropical medicine and pharmaceutical business.
Professional Experience ๐ผ
Currently, Dr. Standaert is the Director of HEBO bv, where he consults in health economics and epidemiology. Previously, he served as Global Health Economic Senior Director at GSK Vaccines, where he developed and managed lifecycle health economics programs for numerous vaccines and collaborated with global health bodies.
Research Interests ๐
Dr. Standaert’s research centers on health economics, particularly in assessing the economic impact of vaccines and optimizing health interventions. His focus areas include infectious disease modeling, cost-effectiveness, and strategies for maximizing healthcare resource allocation.
Awards ๐
Dr. Standaert has received prestigious recognitions for his work, including Best Podium Presentation at ISPOR US 2012 and Best Poster at ISPOR EU 2011, acknowledging his impactful contributions to health economic research.
Publications ๐
Dr. Standaert has authored over 60 peer-reviewed publications, including studies in top journals. Some notable publications include:
Zeevat F et al. (2020). “Incorporating Heterogeneity in Risk for Infection and Disease in Cost-Effectiveness of Preventative Strategies in Older Adults.” Value in Health, cited by other research.
Conclusion
Dr. Baudouin Standaert’s extensive expertise, particularly in vaccine economics and public health evaluation, positions him as a strong candidate for the “Best Researcher Award.” His contributions have significantly shaped the health economics field, and his strategic roles in vaccine development have had meaningful impacts on public health worldwide. Emphasis on expanding the scope of his interdisciplinary collaborations and mentoring could enhance his already substantial impact.